[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2020 Aug 26

PMID 32838492

Citations 3

Authors

Yang Wang

Xiaobin Yuan

Jiayan Xiong

Zhidong Hao

Xingzhe Peng

Wanlin Chen

Lingling Cui

Hua Li

Xiulan Wang

Xiangbo He

Min Yang

Congxin Liang

Yongbin Ma

Lieming Ding

Li Mao

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the most common malignancies with the highest incidence rate and mortality rate worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85%. Only 5% NSCLC patients are anaplastic lymphoma kinase (ALK) rearrangement positive NSCLC, but the prognosis of these patients is poor, and treatment is urgent. Ensartinib (X-396), a next-generation ALK tyrosine kinase inhibitor (ALK-TKI), has shown greater potency on inhibiting ALK activity and controlling brain metastases than crizotinib, which is indicated for the treatment of crizotinib-resistant, ALK-positive NSCLC patients. Several phase I to III clinical trials included both healthy volunteers and NSCLC patients have been conducted both in China and abroad. In this review, we briefly summarized the results of these trials, and preliminary efficacy, safety, pharmacology and pharmacokinetics/pharmacodynamics of ensartinib were discussed.

Citing Articles

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.

Wu J, Lin Z Int J Mol Sci. 2022; 23(23).

PMID: 36499382 PMC: 9738331. DOI: 10.3390/ijms232315056.

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why?.

Kaczmarska A, Sliwa P, Lejman M, Zawitkowska J Int J Mol Sci. 2021; 22(21).

PMID: 34769519 PMC: 8584725. DOI: 10.3390/ijms222112089.

[Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].

Bai H, Han Y, Niu Y, Zhang M Zhongguo Fei Ai Za Zhi. 2021; 24(8):598-604.

PMID: 34344501 PMC: 8387652. DOI: 10.3779/j.issn.1009-3419.2021.101.32.

References

Song Z, Zheng Y, Wang X, Su H, Zhang Y, Song Y . ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. J Thorac Dis. 2017; 9(10):3919-3926. PMC: 5723822. DOI: 10.21037/jtd.2017.09.79. View

Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J . The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22):5527-5538. DOI: 10.1158/1078-0432.CCR-16-0569. View

Shaw A, Kim D, Mehra R, Tan D, Felip E, Chow L . Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(13):1189-97. PMC: 4079055. DOI: 10.1056/NEJMoa1311107. View

Ou S, Ahn J, De Petris L, Govindan R, Yang J, Hughes B . Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2015; 34(7):661-8. DOI: 10.1200/jco.2015.63.9443. View

Kim D, Tiseo M, Ahn M, Reckamp K, Hansen K, Kim S . Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 35(22):2490-2498. DOI: 10.1200/JCO.2016.71.5904. View

Zheng R, Sun K, Zhang S, Zeng H, Zou X, Chen R . [Report of cancer epidemiology in China, 2015]. Zhonghua Zhong Liu Za Zhi. 2019; 41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005. View

Marsilje T, Pei W, Chen B, Lu W, Uno T, Jin Y . Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor.... J Med Chem. 2013; 56(14):5675-90. DOI: 10.1021/jm400402q. View

Tsao A, Scagliotti G, Bunn Jr P, Carbone D, Warren G, Bai C . Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016; 11(5):613-638. DOI: 10.1016/j.jtho.2016.03.012. View

Ning H, Mitsui H, Wang C, Suarez-Farinas M, Gonzalez J, Shah K . Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma. Oncotarget. 2013; 4(12):2237-48. PMC: 3926823. DOI: 10.18632/oncotarget.1357. View

10.

Shaw A, Kim T, Crino L, Gridelli C, Kiura K, Liu G . Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017; 18(7):874-886. DOI: 10.1016/S1470-2045(17)30339-X. View

11.

Friboulet L, Li N, Katayama R, Lee C, Gainor J, Crystal A . The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014; 4(6):662-673. PMC: 4068971. DOI: 10.1158/2159-8290.CD-13-0846. View

12.

Singhi E, Horn L . Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncol. 2018; 14(18):1781-1787. DOI: 10.2217/fon-2017-0619. View

13.

Ponten F, Jirstrom K, Uhlen M . The Human Protein Atlas--a tool for pathology. J Pathol. 2008; 216(4):387-93. DOI: 10.1002/path.2440. View

14.

Yang J, Ou S, De Petris L, Gadgeel S, Gandhi L, Kim D . Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(10):1552-1560. PMC: 6886236. DOI: 10.1016/j.jtho.2017.06.070. View

15.

Hofman P . ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. Cancers (Basel). 2017; 9(8). PMC: 5575610. DOI: 10.3390/cancers9080107. View

16.

Crino L, Ahn M, de Marinis F, Groen H, Wakelee H, Hida T . Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016; 34(24):2866-73. DOI: 10.1200/JCO.2015.65.5936. View

17.

Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H . Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014; 351(2):215-21. DOI: 10.1016/j.canlet.2014.05.020. View

18.

Lovly C, Heuckmann J, de Stanchina E, Chen H, Thomas R, Liang C . Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011; 71(14):4920-31. PMC: 3138877. DOI: 10.1158/0008-5472.CAN-10-3879. View

19.

Gettinger S, Bazhenova L, Langer C, Salgia R, Gold K, Rosell R . Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(12):1683-1696. DOI: 10.1016/S1470-2045(16)30392-8. View

20.

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View